Purpose Of Review: The diagnosis of drug-induced hypersensitivity reactions is a common clinical challenge and the skin is considered a signal organ for a large percentage of these reactions. In order to assure clinical improvement of the patient, nondermatologists in primary or intensive care settings attending to patients receiving several drugs are often confronted with the need for an immediate decision which drug to stop and which drug to continue. As reliable allergological tests are missing for most drugs and are not available for immediate interventions, computer-aided diagnostic systems might be of assistance.
Recent Findings: This review highlights the evolution of automated diagnostic aides in dermatology, emphasizes prerequisites for the development of appropriate computational algorithms and discusses the specific requirements and chances for the development of computer-aided diagnostic systems as a supportive approach in the diagnosis of culprit drugs for putative drug-induced hypersensitivity reactions.
Summary: As complex computational algorithms have to be created integrating both image and data analysis, the development of a computer-aided system for supporting nondermatologists in the diagnosis of drug-related hypersensitivity reactions is an ambitious task but might represent an achievable goal for the medium-term future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ACI.0b013e32834a974c | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Case of Allergic Contact Dermatitis Due to Chrysanthemum After Guselkumab Therapy for Palmoplantar Pustulosis.
Cureus
December 2024
Department of Dermatology, Asahikawa Medical University, Asahikawa, JPN.
Eczematous paradoxical reactions are commonly associated with anti-interleukin-17A (anti-IL-17A) antibodies. However, IL-23 p19 inhibitors can also cause similar cutaneous manifestations. We present a case of a 77-year-old Japanese woman with palmoplantar pustulosis (PPP), who developed eczematous lesions on her face, neck, and dorsum of the hands 10 weeks after initiating guselkumab treatment.
View Article and Find Full Text PDFFrom Fibrosis to Granuloma: Drug Induced Systemic Sarcoidosis-Like Reaction After Rituximab in a Patient with Primary Sjögren's Syndrome.
Eur J Case Rep Intern Med
December 2024
Clínica de Medicina, Serviço de Medicina Interna, Centro Hospitalar Universitário de Santo António, Porto, Portugal.
Unlabelled: Sarcoidosis is a multisystemic syndrome characterized by non-caseous granulomatous inflammation, although necrotizing sarcoid granulomatosis is considered part of the spectrum of the disease. Drug induced sarcoidosis-like reaction (DISR) is a systemic granulomatous reaction, which is histopathologically identical to primary sarcoidosis - mostly described after the use of biologics like tumour necrosis factor alpha antagonists but also anti-CD20 (rituximab). The authors present the very rare case of a woman with a primary Sjögren's syndrome (pSS) started on rituximab for disease control, which evolved with a 3-year indolent progressive systemic sarcoid reaction.
View Article and Find Full Text PDFExploratory disproportionality analysis of potentially drug-induced eosinophilic pneumonia using United States Food and Drug Administration adverse event reporting system.
Sci Rep
January 2025
Department of Pharmacology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Drug-induced eosinophilic pneumonia (EP) is an uncommon adverse drug reaction. Many drugs have been reported to cause EP, the evidence mainly being in the form of case reports/case series. This study aims to conduct an exploratory analysis of the United States Food and Drug Administration adverse event reporting system (FAERS) database to identify previously unknown drugs that can cause EP and supplement the available evidence for known culprit drugs.
View Article and Find Full Text PDF[Consensus on the management of liver injury associated with targeted drugs and immune checkpoint inhibitors for hepatocellular carcinoma ( version 2024)].
Zhonghua Gan Zang Bing Za Zhi
December 2024
With the widespread application of systemic treatments for hepatocellular carcinoma, liver injury caused by molecular targeted drugs and immune checkpoint inhibitors has become a common clinical problem. The Chinese Society of Hepatology organized relevant domestic experts to summarize and analyze the adverse liver reactions and diagnosis and treatment progress related to systemic treatment of liver cancer at home and abroad, and formulated the "Consensus on the management of liver injury associated with targeted drugs and immune checkpoint inhibitors for hepatocellular carcinoma," aiming to provide reasonable suggestions and decision-making references for clinical physicians in liver disease and related specialties in the monitoring, diagnosis, prevention and treatment of liver injury during the treatment of targeted drugs and immune checkpoint inhibitors for hepatocellular carcinoma, so as to enable more liver cancer patients to benefit from targeted immune therapy.
View Article and Find Full Text PDFVanin-1-Activated Fluorescent Probe for Real-Time Imaging of Inflammatory Responses Across Multiple Tissue Types.
Anal Chem
January 2025
College of Chemistry, Jilin Province Research Center for Engineering and Technology of Spectral Analytical Instruments, Jilin University, Qianjin Street 2699, Changchun 130012, China.
Vanin-1 is a pantetheine hydrolase that plays a key role in inflammatory diseases. Effective tools for noninvasive, real-time monitoring of Vanin-1 are lacking, largely due to background fluorescence interference in existing probes. To address this issue, we developed a dual-modal fluorescent and colorimetric probe, MB-Van1, to detect Vanin-1 with high sensitivity and selectivity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!